Levaquin Label Update

The FDA updated the Levaquin label last week.

June 28, 2019, the FDA updated the Levaquin label MEDICATION GUIDE which is the information given to patients.

The FDA added more psychiatric adverse event warnings to the MEDICATION GUIDE including:

Feeling agitated
Reduced awareness of surroundings
Memory problems
False or strange thoughts or beliefs (delusions)

The June 28, 2019 MEDICATION GUIDE also now states that “Tendon problems may be permanent.”

By Admin|2019-07-03T14:09:37-05:00July 3rd, 2019|FDA|3 Comments

About the Author: Admin

David experienced an adverse event to the the fluoroquinolone Levaquin in 2007 at age 46. Prior to, he was a healthy law enforcement official. Now, disabled with drug induced mitochondrial disease/dysfunction, he is an FQ patient safety advocate, citizen scientist, FQ researcher, author, and commentator. He has contributed to case studies and published academic papers on the FQ’s in the BMJ, European Journal of Medicine, The Journal of Community and Supportive Oncology, Oxford Academic Clinical infectious Diseases, and contributed data to many more outlets.

3 Comments

Geoffrey Comer July 5, 2019 at 9:27 am - Reply

Hi How can I get a copy of this update? I have searched the FDA site but cannot find it. We live in the UK and my wife was floxed in Spain 9 years ago. Most doctors here don’t recognise the warnings and we battle on. Your site is a tremendous help and support
Joan M. Bauer July 5, 2019 at 12:49 pm - Reply

I had a terrible time with it, spent some time in the hospital.
Cw July 5, 2019 at 7:07 pm - Reply

My chiropractor recently told me he was once prescribed Levaquin and all he could think of was driving his car off a bridge. This was quite awhile ago. He immediately called his doc who told him to stop taking it immediately. Wish other docs would have been as smart.